SK Biopharm announced that it will double U.S. sales of Cenobamate (Xcopri) this year. Cho Jung-woo, CEO of SK Biopharm, presented this year's goal at an online press conference on the 24th. SK Biopharm generated 78.2 billion won in sales from Cenobamate in the U.S. last year. Sales have more than increased seven times compared to 10.6 billion won in 2020, the first year of its launch.

SK Biopharm plans to double its sales to 160 billion won this year. New marketing plan has been drawn up this year. First of all, the government plans to double the annual number of prescriptions from 90,000 last year to about 90,000 this year. If the company focused on increasing the new prescription rate of doctors who